1. An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma. Issue 6 (27th October 2021) Authors: De Meulenaere, Astrid; Vermassen, Tijl; Creytens, David; De Keukeleire, Stijn; Delahaye, Tim; Deron, Philippe; Duprez, Fréderic; Fung, Samson; Pauwels, Patrick; Ferdinande, Liesbeth; Rottey, Sylvie Journal: Clinical and translational science Issue: Volume 14:Issue 6(2021) Page Start: 2300 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Issue 6 (June 2018) Authors: Pernas, Sonia; Martin, Miguel; Kaufman, Peter A; Gil-Martin, Marta; Gomez Pardo, Patricia; Lopez-Tarruella, Sara; Manso, Luis; Ciruelos, Eva; Perez-Fidalgo, Jose Alejandro; Hernando, Cristina; Ademuyiwa, Foluso O; Weilbaecher, Katherine; Mayer, Ingrid; Pluard, Timothy J; Martinez Garcia, Maria; V... Journal: Lancet oncology Issue: Volume 19:Issue 6(2018) Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗